{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:31:08Z","timestamp":1792161068703,"version":"4.4.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Apolipoprotein C-II (apoC-II) is a critical cofactor for the activation of lipoprotein lipase (LPL), a plasma enzyme that hydrolyzes triglycerides (TG) on TG-rich lipoproteins (TRL). Although apoC-II was first discovered nearly 50 years ago, there is renewed interest in it because of the recent efforts to develop new drugs for the treatment of hypertriglyceridemia (HTG). The main topic of this review will be the development of apoC-II mimetic peptides as a possible new therapy for cardiovascular disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>We first describe the biochemistry of apoC-II and its role in TRL metabolism. We then review the clinical findings of HTG, particularly those related to apoC-II deficiency, and how TG metabolism relates to the development of atherosclerosis. We next summarize the current efforts to develop new drugs for HTG. Finally, we describe recent efforts to make small synthetic apoC-II mimetic peptides for activation of LPL and how these peptides unexpectedly have other mechanisms of action mostly related to the antagonism of the TG-raising effects of apoC-III.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The role of apoC-II in TG metabolism is reviewed, as well as recent efforts to develop apoC-II mimetic peptides into a novel therapy for HTG.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000680","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T07:52:42Z","timestamp":1587628362000},"page":"147-153","source":"Crossref","is-referenced-by-count":53,"title":["Apolipoprotein C-II: the re-emergence of a forgotten factor"],"prefix":"10.1097","volume":"31","author":[{"given":"Anna","family":"Wolska","sequence":"first","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart","family":"Reimund","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"TG-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"TG-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MOL.0000000000000297","article-title":"Role of lipoprotein lipase in lipid metabolism","volume":"27","author":"Olivecrona","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","article-title":"Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in TG metabolism","volume":"267","author":"Wolska","year":"2017","journal-title":"Atherosclerosis"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1016\/S0021-9258(18)62574-8","article-title":"Further characterization of apolipoproteins from the human plasma very low density lipoproteins","volume":"245","author":"Brown","year":"1970","journal-title":"J Biol Chem"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0021-9258(18)66012-0","article-title":"Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil","volume":"215","author":"Korn","year":"1955","journal-title":"J Biol Chem"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.114.220418","article-title":"A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum TGs in apolipoprotein E-knockout mice","volume":"352","author":"Amar","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.115.229740","article-title":"Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide","volume":"356","author":"Sakurai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"7078241","DOI":"10.1155\/2019\/7078241","article-title":"Apolipoprotein C-II mimetic peptide promotes the plasma clearance of TG-rich lipid emulsion and the incorporation of fatty acids into peripheral tissues of mice","volume":"2019","author":"Komatsu","year":"2019","journal-title":"J Nutr Metab"},{"key":"R10-20230917","first-page":"989","article-title":"Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia","volume":"8","author":"Liu","year":"2015","journal-title":"Dis Model Mech"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"pii: eaaw7905","DOI":"10.1126\/scitranslmed.aaw7905","article-title":"A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma TGs","volume":"12","author":"Wolska","year":"2020","journal-title":"Sci Transl Med"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2019.08.130","article-title":"Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach","volume":"519","author":"Reimund","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1373\/clinchem.2008.108175","article-title":"High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance","volume":"54","author":"Hortin","year":"2008","journal-title":"Clin Chem"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.metabol.2011.12.002","article-title":"A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease","volume":"61","author":"Kei","year":"2012","journal-title":"Metabolism"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1021\/bi002821m","article-title":"NMR structure of human apolipoprotein C-II in the presence of sodium dodecyl sulfate","volume":"40","author":"MacRaild","year":"2001","journal-title":"Biochemistry"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1021\/bi0267184","article-title":"Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase","volume":"42","author":"Zdunek","year":"2003","journal-title":"Biochemistry"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1073\/pnas.74.11.4848","article-title":"Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II","volume":"74","author":"Kinnunen","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.ATV.17.8.1545","article-title":"Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons","volume":"17","author":"Olivecrona","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cmet.2014.01.017","article-title":"The GPIHBP1-LPL complex is responsible for the margination of TG-rich lipoproteins in capillaries","volume":"19","author":"Goulbourne","year":"2014","journal-title":"Cell Metab"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cmet.2010.04.016","article-title":"GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries","volume":"12","author":"Davies","year":"2010","journal-title":"Cell Metab"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1194\/jlr.R800085-JLR200","article-title":"Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways","volume":"50 Suppl","author":"Goldberg","year":"2009","journal-title":"J Lipid Res"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"18029","DOI":"10.1074\/jbc.M114.629865","article-title":"A pressure-dependent model for the regulation of lipoprotein lipase by apolipoprotein C-II","volume":"290","author":"Meyers","year":"2015","journal-title":"J Biol Chem"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0022-2275(20)37316-8","article-title":"Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects","volume":"22","author":"Huff","year":"1981","journal-title":"J Lipid Res"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1074\/jbc.M105421200","article-title":"Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase","volume":"277","author":"Shen","year":"2002","journal-title":"J Biol Chem"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1432-1033.1980.tb04602.x","article-title":"Lipoprotein lipase: some effects of activator proteins","volume":"106","author":"Bengtsson","year":"1980","journal-title":"Eur J Biochem"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/er.2014-1062","article-title":"Hypertriglyceridemia in the genomic era: a new paradigm","volume":"36","author":"Lewis","year":"2015","journal-title":"Endocr Rev"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pathol.2018.10.014","article-title":"The role of genetic testing in dyslipidaemia","volume":"51","author":"Berberich","year":"2019","journal-title":"Pathology"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000482","article-title":"Polygenic influences on dyslipidemias","volume":"29","author":"Dron","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00002018-200124060-00003","article-title":"Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels","volume":"24","author":"Mantel-Teeuwisse","year":"2001","journal-title":"Drug Saf"},{"key":"R30-20230917","article-title":"Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency","author":"Brunzell","year":"2019","journal-title":"The online metabolic and molecular bases of inherited disease"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.10702","article-title":"Diagnosis and management of type I and type V hyperlipoproteinemia","volume":"19","author":"Gotoda","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia--current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/ATVBAHA.118.312028","article-title":"Moving targets: recent advances in lipid-lowering therapies","volume":"39","author":"Larsen","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.4390","article-title":"A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower TG-rich lipoprotein levels","volume":"23","author":"Khetarpal","year":"2017","journal-title":"Nat Med"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma TGs in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces TGs in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"R43-20230917","first-page":"CD009753","article-title":"Fibrates for primary prevention of cardiovascular disease events","volume":"11","author":"Jakob","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"32273","DOI":"10.1074\/jbc.M804461200","article-title":"Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides","volume":"283","author":"Sethi","year":"2008","journal-title":"J Biol Chem"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1194\/jlr.D071787","article-title":"Lipoprotein lipase activity and interactions studied in human plasma by isothermal titration calorimetry","volume":"58","author":"Reimund","year":"2017","journal-title":"J Lipid Res"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1172\/JCI117151","article-title":"Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice","volume":"93","author":"Shachter","year":"1994","journal-title":"J Clin Invest"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:02:23Z","timestamp":1694937743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000680","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}